Regulatory
MEDIUMTrigger: Labour Code compliance created a discrete one-time charge; not a structural margin issue, but demonstrates regulatory cost risk in healthcare operations
Monitor: regulatory
Fortis Healthcare Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +12.7%Weak
In , Fortis Healthcare Ltd (Hospitals) is outperforming Nifty 500 with +12.7% relative strength. Fundamentals: Weak.
Fortis Healthcare Ltd Key Facts
- PE Ratio
- 69.1x
- Market Cap
- ₹69,679 Cr
- PAT Growth YoY
- -22%
- Revenue Growth YoY
- +18%
- OPM
- 22.0%
- RS vs Nifty 500
- +12.7%
PE: Early ExpansionRiding Wave
What's Happening
📊PE near cycle lows — valuation reset is underway
📊Debt increased 29% YoY — leverage rising
🌐FII stake increased 2.6% this quarter
🏛️DII reducing — stake down 1.6%
💰Trading 80% above estimated fair value — significant premium
Key Risks
1. Regulatory
MEDIUM2. Labor
MEDIUM3. Geopolitical
LOWKey Numbers
PAT Growth YoY
-22%
Stable
Revenue YoY
+18%
Accelerating
Operating Margin
22.0%
+300 bps YoY
PE Ratio
69.1
Current Price
₹923
Dividend Yield
0.11%
Fundamental Score
36/100
Weak
3Y PAT CAGR
+1%
Market Cap
71.9K Cr
Valuation
Significantly Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
What Are the Key Risks for Fortis Healthcare Ltd?
Earnings deceleration risks from management commentary
Labor
MEDIUMTrigger: Clinician attrition is a direct revenue risk at acquired hospitals — each senior doctor departure can pull patient volumes; Gleneagles is a multi-facility acquisition and the turnaround is taking longer than expected
Monitor: labor
Geopolitical
LOWTrigger: International patient revenue limited by geopolitical volatility; diversification into Africa/Central Asia reduces dependence on traditional Middle East/Bangladesh sources
Monitor: geopolitical
Regulatory
LOWTrigger: Government insurance pricing (CGHS/ECHS) rate hike benefit is real but execution-dependent on regulatory implementation timelines — delays push FY27 benefit into FY28
Monitor: regulatory
What Is Fortis Healthcare Ltd's Management Saying?
Key quotes from recent conference calls
“The decline in PAT was primarily due to the one-off expense for the quarter INR55 crores pertaining to New Labour Codes, offset by reversal of impairment in an associated company amounting to INR9 crores [Risk (regulatory): MEDIUM]”
“Nine months growth is actually negative for the unit we are looking at. It is almost 4% negative. And there are a lot of disturbance. There is clinician attrition. Management team has also been changed [Risk (labor): MEDIUM]”
“the international traffic is subject to so many other geopolitical situations, which are continuously evolving right now, so I think one cannot really bank on that [Risk (geopolitical): LOW]”
“if you have gone through that circular for CGHS, there is a super specialty hospital category for which the registration yet not have been opened. So all those things will be finalized maybe by next year [Risk (regulatory): LOW]”
How Fast Is Fortis Healthcare Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +18% | +11% | Accelerating |
| PAT (Net Profit) | -22% | +1% | Stable |
| OPM | 22.0% | +300 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 30, 2026.
Other Top Hospitals Stocks Beating Nifty 500
Frequently Asked Questions: Fortis Healthcare Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were Fortis Healthcare Ltd's latest quarterly results?
Fortis Healthcare Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: -22.4% (stable)
- Revenue Growth YoY: +17.5%
- Operating Margin: 22.0% (volatile)
Is Fortis Healthcare Ltd's profit growing or declining?
Fortis Healthcare Ltd's profit is declining with an stable trend.
- PAT Growth YoY: -22.4% (latest quarter)
- PAT Growth QoQ: -40.1% (sequential)
- 3-Year PAT CAGR: +0.8%
- Trend: Stable — consistent growth pattern
What is Fortis Healthcare Ltd's revenue growth trend?
Fortis Healthcare Ltd's revenue growth trend is accelerating.
- Revenue Growth YoY: +17.5%
- Revenue Growth QoQ: -2.8% (sequential)
- 3-Year Revenue CAGR: +10.8%
How is Fortis Healthcare Ltd's operating margin trending?
Fortis Healthcare Ltd's operating margin is volatile.
- Current OPM: 22.0%
- OPM Change YoY: +3.0% basis points
- OPM Change QoQ: -2.0% basis points
What is Fortis Healthcare Ltd's 3-year profit and revenue CAGR?
Fortis Healthcare Ltd's long-term compounding rates
- 3-Year Profit CAGR: +0.8%
- 3-Year Revenue CAGR: +10.8%
Is Fortis Healthcare Ltd's growth accelerating or decelerating?
Fortis Healthcare Ltd's earnings growth is stable with weakening on a sequential basis.
- YoY Acceleration: -92.9% bps
- Sequential Acceleration: -63.3% bps
- Note: YoY and QoQ trends are diverging — worth monitoring
What is Fortis Healthcare Ltd's trailing twelve month (TTM) performance?
Fortis Healthcare Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹981 Cr
- TTM PAT Growth: +19.1% YoY
- TTM Revenue: ₹9,000 Cr
- TTM Revenue Growth: +16.0% YoY
- TTM Operating Margin: 22.8%
Is Fortis Healthcare Ltd overvalued or undervalued?
Fortis Healthcare Ltd appears significantly overvalued based on our fair value analysis.
- Valuation Signal: Significantly Overvalued
- Current PE: 69.1x
- Price-to-Book: 7.4x
What is Fortis Healthcare Ltd's current PE ratio?
Fortis Healthcare Ltd's current PE ratio is 69.1x.
- Current PE: 69.1x
- Market Cap: 69.7K Cr
- Dividend Yield: 0.11%
How does Fortis Healthcare Ltd's valuation compare to its history?
Fortis Healthcare Ltd's current PE is 69.1x.
- Current PE: 69.1x
- Valuation Assessment: Significantly Overvalued
What is Fortis Healthcare Ltd's price-to-book ratio?
Fortis Healthcare Ltd's price-to-book ratio is 7.4x.
- Price-to-Book (P/B): 7.4x
- Book Value per Share: ₹125
- Current Price: ₹923
Is Fortis Healthcare Ltd a fundamentally strong company?
Fortis Healthcare Ltd is rated Weak with a fundamental score of 36.1/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +17.5% (10% weight)
- PAT Growth YoY: -22.4% (10% weight)
- PAT Growth QoQ: -40.1% (10% weight)
- Margins stable (10% weight)
Is Fortis Healthcare Ltd debt free?
Fortis Healthcare Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹2,000 Cr
What is Fortis Healthcare Ltd's return on equity (ROE) and ROCE?
Fortis Healthcare Ltd's return ratios over recent years
- FY2023: ROCE 10.0%
- FY2024: ROCE 10.0%
- FY2025: ROCE 12.0%
Is Fortis Healthcare Ltd's cash flow positive?
Fortis Healthcare Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹1,000 Cr
- Free Cash Flow (FCF): ₹644 Cr
- CFO/PAT Ratio: 176% (strong cash conversion)
What is Fortis Healthcare Ltd's dividend yield?
Fortis Healthcare Ltd's current dividend yield is 0.11%.
- Dividend Yield: 0.11%
- Current Price: ₹923
Who holds Fortis Healthcare Ltd shares — promoters, FII, DII?
Fortis Healthcare Ltd's shareholding pattern (Mar 2026)
- Promoters: 31.2%
- FII (Foreign): 26.0%
- DII (Domestic): 31.4%
- Public: 11.5%
Is promoter holding increasing or decreasing in Fortis Healthcare Ltd?
Fortis Healthcare Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 31.2% (Mar 2026)
- Previous Quarter: 31.2% (Dec 2025)
- Change: 0.00% (stable)
How long has Fortis Healthcare Ltd been outperforming Nifty 500?
Fortis Healthcare Ltd has been outperforming Nifty 500 for 3 consecutive weeks, indicating early-stage outperformance.
Is Fortis Healthcare Ltd a new momentum entry or an established outperformer?
Fortis Healthcare Ltd is an established outperformer with 3 weeks of consecutive Nifty 500 outperformance.
What are the key risks in Fortis Healthcare Ltd?
Fortis Healthcare Ltd has 4 key risks worth monitoring
- [MEDIUM] Regulatory — Labour Code compliance created a discrete one-time charge; not a structural margin issue, but demonstrates regulatory cost risk in healthcare operations
- [MEDIUM] Labor — Clinician attrition is a direct revenue risk at acquired hospitals — each senior doctor departure can pull patient volumes; Gleneagles is a multi-facility acquisition and the turnaround is taking longer than expected
- [LOW] Geopolitical — International patient revenue limited by geopolitical volatility; diversification into Africa/Central Asia reduces dependence on traditional Middle East/Bangladesh sources
- [LOW] Regulatory — Government insurance pricing (CGHS/ECHS) rate hike benefit is real but execution-dependent on regulatory implementation timelines — delays push FY27 benefit into FY28
What did Fortis Healthcare Ltd's management say in the latest earnings call?
In Q3 FY26, Fortis Healthcare Ltd's management highlighted
- "The decline in PAT was primarily due to the one-off expense for the quarter INR55 crores pertaining to New Labour Codes, offset by reversal of impairm..."
- "Nine months growth is actually negative for the unit we are looking at. It is almost 4% negative. And there are a lot of disturbance. There is clinici..."
- "the international traffic is subject to so many other geopolitical situations, which are continuously evolving right now, so I think one cannot really..."
Is Fortis Healthcare Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Fortis Healthcare Ltd may be worth studying
- Revenue growth is accelerating — +17.5% YoY
- Cash flow is positive — CFO ₹1,000 Cr
What is the investment thesis for Fortis Healthcare Ltd?
Fortis Healthcare Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +17.5% YoY
Risk Factors (Bear Case)
- Appears significantly overvalued
- Key risk: Regulatory
What is the future outlook for Fortis Healthcare Ltd?
Fortis Healthcare Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: accelerating
- Margin Trend: volatile
- Valuation: Significantly Overvalued
- Key Risk: Regulatory
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.